Objective: 11A-Hydroxysteroid dehydrogenase type I (11AHSD1) regenerates active cortisol from inert cortisone in adipose tissue. Elevated adipose tissue 11AHSD1 activity is observed in obese humans and rodents, where it is linked to obesity and its metabolic consequences. Menopause is also associated with increased abdominal fat accumulation, suggesting that estrogen is also important in adipose tissue metabolism. The purpose of this current study was to establish whether estrogen signaling through estrogen receptor > (ER->) and estrogen receptor A (ER-A) could influence 11AHSD1 in premenopausal and postmenopausal adipose tissues.
T he onset of menopause is associated with accumulation of adipose tissue, 1 which may contribute to the increased metabolic and cardiovascular risks seen in postmenopausal women. Chronic glucocorticoid excess (eg, in Cushing's syndrome) also causes obesity and its associated metabolic dysfunction. Although plasma cortisol levels are not elevated in obesity, 2 recent evidence suggests that there is a selective increase in glucocorticoid regeneration in adipose tissue. 3 Specifically, the microsomal enzyme 11A-hydroxysteroid dehydrogenase type I (11AHSD1), which catalyzes the intracellular reactivation of cortisol from inert cortisone, is selectively increased in adipose tissue in obese humans and rodent models of obesity. 4, 5 This seems to be of pathophysiological importance because mice engineered to selectively overexpress 11AHSD1 in adipose tissue develop visceral obesity and metabolic syndrome, 6 whereas mice lacking 11AHSD1 resist glucose intolerance, insulin resistance, and hyperlipidemia on high-fat diet. 7 In humans, 11AHSD1 inhibition has analogous effects. 8 Estrogen signaling is predominantly mediated via the two nuclear estrogen receptors > and A (ER-> and ER-A), both of which are present in human adipose tissue. 9 Human studies on the sex steroid control of 11AHSD1 in adipose tissue are scarce and inconclusive, reporting both up-regulation and no effect of estrogen, using a variety of doses mainly in vitro. 10 Here we have explored the possibility of a functional link between ER->/ER-A signaling and 11AHSD1 expression/activity in adipose tissue from premenopausal and postmenopausal women.
METHODS

Experiments in humans
All women gave a written informed consent form, and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. The study of premenopausal and postmenopausal women was approved by the Ethical Committee for Human Research at Umeå University (Umeå, Sweden; approval ID 03-339). Nineteen premenopausal and 23 postmenopausal, healthy, normal-weight women were recruited by advertisements in local newspapers and within the Umeå University Hospital and campus areas. Exclusion criteria were as follows: diabetes, thyroid dysfunction, hepatic and renal diseases, and use of tobacco, hormonal contraceptives, systemic gonadal hormone therapy, or oral glucocorticoid medication. None of the postmenopausal women reported menstrual periods within the last 12 months. One premenopausal woman used inhaled steroids for asthma (budesonide, 400 Kg/24 h). Three postmenopausal women had well-controlled hypertension treated with A-blockers, diuretics, or calcium antagonists; one woman took tolterodine for urinary incontinence and bisphosphonates for osteoporosis; and two women used topical estradiol or estriol treatment. Further details on the participants included in this study have been described previously. 11 
Clinical protocol
Premenopausal women were evaluated during the follicular phase of the menstrual cycle to negate the possible effects of hormonal fluctuations. Menstrual phase or postmenopause status was confirmed by measuring serum 17A-estradiol and progesterone levels, as described below.
Anthropometric measurements and adipose tissue biopsies were performed on separate days. Weight to the nearest 0.1 kg (with participants wearing light clothes) and height and waist circumferences to the nearest 0.5 cm were measured. Body composition was measured by bioelectrical impedance analysis using a Bodystat 1500 (Bodystat Ltd., Isle of Man, British Isles). Approximately 2 g of periumbilical superficial subcutaneous adipose tissue was excised under local anesthesia with lidocaine (Xylocaine without adrenaline; AstraZeneca, Södertälje, Sweden) after an overnight fast. Tissue was snapfrozen in liquid nitrogen within 5 minutes of removal and stored at j80-C until further analyses.
Venous blood samples for routine laboratory tests were drawn at the time of anthropometric measurements. Venous blood samples for serum analyses (as described below) were drawn in the mornings of the adipose tissue biopsies after at least 8 hours of fasting.
Laboratory methods
Serum analysis
17A-Estradiol, progesterone, and cortisol were measured in samples drawn at the time of biopsy. Serum cortisol and progesterone were analyzed by electrochemiluminescence immunoassays on a Modular Analytics E170 (all from Roche AB, Stockholm, Sweden). 17A-Estradiol was measured using an ultrasensitive radioimmunoassay (ESTR-US-CT; CIS bio international, Gif-sur-Yvette Cedex, France; intra-assay and interassay coefficients of variation, 2.8%-18.1% and 5.8%-17.6%, respectively).
Cell culture
Human Simpson-Golabi-Behmel syndrome (SGBS) adipocyte cells, which have previously been shown to express both ER-> and ER-A, 12 were maintained and differentiated into adipocytes, as previously described. 13 For experimental manipulations, cells were serum-starved overnight in phenol redYfree medium containing 0.1% bovine serum albumin. After serum starvation, cells were treated with diarylpropiolnitrile (DPN) or propyl pyrazole triol (PPT) at the concentrations indicated for 24 hours. All experiments were performed in triplicate and repeated three times.
Quantification of messenger RNA
Total RNA was extracted from snap-frozen adipose tissues or SGBS adipocytes, using an RNeasy lipid tissue midi kit (Qiagen Nordic, Qiagen House, West Sussex, UK), according to the manufacturer's protocol. RNA concentrations were measured on an ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Integrity was evaluated on a 1% agarose electrophoretic gel and visualized with ethidium bromide under UV light.
One microgram of RNA was reverse-transcribed into complementary DNA (cDNA) using TaqMan Reverse Transcription Reagents (Roche Molecular Systems, Inc., Branchburg, NJ). cDNA was incubated in triplicate with 1Â gene-specific assay mix (Applied Biosystems, Warrington, UK) in 1Â Universal PCR Master Mix (Roche). Polymerase chain reaction cycling and detection of fluorescent signal were carried out on an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Triplicates were deemed acceptable if the SD of the crossing point was G0.5 cycles. A standard curve (y axis, crossing point; x axis, log concentration) for each gene was generated by serial dilution of cDNAs pooled from different samples, fitted into a straight line, and deemed acceptable if the reaction efficiency was between 1.7 and 2.1. For SGBS cells, results were corrected for TATA box binding protein, whereas for human adipose tissue, results were corrected for cyclophilin A, which had the lowest coefficients of variation and the best stability value based on the Normfinder algorithm (http://www.mdl.dk/publicationsnormfinder.htm) among three tested endogenous controls.
The prevalidated assays used were as follows: human ER->, Hs00174860_m1; human ER-A, Hs00230957_m1; human 11AHSD1, Hs01547870_m1; cyclophilin A (endogenous control), Hs99999904_m1; and TATA box binding protein (endogenous control), Hs00427620_m1 (all from Applied Biosystems).
Western blot analysis
SGBS cells were washed in ice-cold phosphate-buffered saline, and lysates were prepared as described previously. 13 Fifty micrograms of protein was diluted in a sample buffer containing dithiothreitol, denatured, run on 12% polyacrylamide gels, and transferred to nitrocellulose for Western blot analysis. Membranes were probed with 11AHSD1 antibody (The Binding Site Group Ltd., Birmingham, UK). Protein loading was corrected for using a monoclonal antibody against A-tubulin (Millipore, Watford, UK). Proteins were visualized with an Alexa Fluor secondary antibody (Li-cor Biosciences, Cambridge, UK), and band intensities were quantified using the Odyssey infrared imaging system (Li-cor Biosciences).
Enzymology
11AHSD1 activity was measured in the 11A-reductase direction in intact differentiated SGBS adipocytes. A total of 3 Â 10 5 cells/well in six-well plates were differentiated as described above. Each well was incubated at 37-C in 2 mL of serum-and phenol redYfree medium containing 1 pM [gH]cortisone (GE Healthcare, Aylesbury, UK) and 1 KM cortisone (Sigma-Aldrich Company Ltd., Dorset, UK). All incubations were performed in triplicate for 24 hours. Assay conditions were optimized to ensure first-order kinetics. After incubation, steroids were extracted from 2 mL of medium with Sep-Pak columns (C 18 , 0.3 g; Waters, Milford, MA). The organic phase was evaporated under nitrogen, and extracts were resuspended in mobile phase (60% water, 10% acetonitrile, and 30% methanol). The percentage of recovery was 90% T 2.3% for cortisone and 92% T 3.1% for cortisol. Steroids were separated by high-performance liquid chromatography (Waters) and compared with known tritiated standards (GE Healthcare) using a C 18 reverse-phase column (Sunfire C 18 , 15 cm, 2.6 mm inner diameter, 5 Km pore size; Waters) and quantified by online liquid scintillation counting.
Statistical analysis
Data are presented as mean T SEM, unless stated otherwise, and were natural logYtransformed when necessary to achieve parametric distributions. Unpaired Student's t tests were used to compare the means between groups. Associations between parameters were assessed using r. Partial correlation analysis was used in all groups to adjust for obesity measures. Statistical calculations were performed using SPSS software (release 14.0.1; SPSS Inc., Chicago, IL). P G 0.05 was considered statistically significant.
RESULTS
Participant characteristics
The percentage of body fat and the waist-to-hip ratio were significantly higher in postmenopausal women compared with premenopausal women (Table 1) . Serum estradiol and progesterone levels were significantly lower in postmenopausal versus premenopausal women regardless of menstrual phase ( Table 1 ). Serum cortisol levels were not different between premenopausal and postmenopausal women. Notably, there was a high variability regarding ER-A and 11AHSD1 expression in the postmenopausal study group.
ER-A and 11AHSD1 messenger RNA levels are increased in adipose tissue from postmenopausal women
There was no difference in the levels of ER-> messenger RNA (mRNA) between premenopausal and postmenopausal women (Fig. 1A) . The expression levels of ER-A and 11AHSD1 mRNA in the follicular phase were twofold higher in postmenopausal women compared with premenopausal women (Fig. 1A) .
11AHSD1 mRNA is correlated with ER-A, but not ER->, mRNA in adipose tissue
A strong positive correlation between 11AHSD1 and ER-A mRNA levels was observed in subcutaneous adipose tissue irrespective of menopause status (Fig. 1B) . These associations remained after adjustments for obesity measures (body mass index, waist, and fat percentage) had been made. In contrast, no association between ER-> and 11AHSD1 expression was found (Fig. 1C) .
Adipocyte 11AHSD1 expression and activity are up-regulated by an ER-A agonist in vitro
The ER-AYspecific agonist DPN up-regulated 11AHSD1 mRNA in human SGBS adipocytes ( Fig. 2A) . In contrast, the ER->Yspecific agonist propyl pyrazole triol did not have any effect on 11AHSD1 mRNA levels ( Fig. 2A) . 11AHSD1 protein expression ( Fig. 2B) and activity (Fig. 2C) were also increased by DPN.
DISCUSSION
These results identify a potential mechanism by which estrogens acting via ER-A may enhance local glucocorticoid action in the adipose tissue of postmenopausal women, including up-regulation of adipose 11AHSD1 expression. This association between ER-A and 11AHSD1 was greatest in adipose tissue from postmenopausal women. Crucially, a direct 
effect of ER-A selective activation on adipocyte 11AHSD1 expression and activity was demonstrated in vitro.
In postmenopausal women, in whom ovarian steroid biosynthesis has ceased, the major source of estrogens is the local aromatase expression in adipose tissue, the function of which increases with age. 14 We previously reported a positive association between aromatase and 11AHSD1 gene expression in adipose tissue, suggesting an up-regulatory effect of local estrogen production on 11AHSD1 expression in adipose tissue. 11 Estrogen signaling is predominantly mediated via the two nuclear receptors ER-> and ER-A, both of which are present in human adipose tissue. 9 Here, we have shown that ER-A mRNA levels are twofold higher in subcutaneous adipose tissue from postmenopausal women compared with premenopausal women and that expression of this receptor is strongly correlated with adipose expression of 11AHSD1. Consequently, in postmenopausal women, adipose 11AHSD1 may be increased by local estrogens acting via ER-A, resulting in increased levels of active glucocorticoids in adipose tissue. Because increased glucocorticoid activity in adipose tissue is associated with obesity, 4 this mechanism may contribute to the increase in body fat observed in our cohort of postmenopausal women. Furthermore, aromatase promoter activity is driven by glucocorticoids, hence increased 11AHSD1 activity in adipose tissue will further amplify this process. The reasons for the high variability in ER-A and 11AHSD1 gene expression among postmenopausal women are not clear and need further studies regarding putative regulatory factors, including a possible interaction with aromatase activity.
Despite the significant increases in the percentage of fat mass and the waist-to-hip ratio in postmenopausal women, the body mass indices of both groups of women were within the reference range, probably reflecting a decrease in lean mass and bone mineral density, which is commonly associated with menopause. 15 11AHSD1 activity has been shown to be increased in the adipose tissue of even moderately obese women. 4 On the other hand, it has been reported that there is no significant correlation between the respective levels of ER-> or ER-A in subcutaneous or omental adipose tissue and obesity. 16 We have had an opportunity to assess this correlation in the subcutaneous and visceral adipose tissues of obese premenopausal women, and there remains a strong association between ER-A and 11AHSD1 in both depots (unpublished results). Therefore, we would predict that the correlation between ER-A and 11AHSD1 in obese women would still remain. Unfortunately, we did not have the opportunity to assess whether there is an association between ER-A and 11AHSD1 expression in visceral adipose tissue in this cohort of women. This would have been interesting because redistribution of adipose tissue to abdominal visceral depots is commonly observed with menopause. Several human studies have shown a higher expression of 11AHSD1 in the subcutaneous depot than in other depots. Furthermore, the subcutaneous depot seems to be more predictive for obesity and metabolic parameters. 17 Importantly, subcutaneous 11AHSD1 correlates with measures of central fat accumulation and is an independent predictor for central fat accumulation, 17 emphasizing the important role of the 11AHSD1 enzyme in subcutaneous adipose tissue.
This observation of a proadipogenic role for ER-A is supported by studies in knockout mice. ER-> knockout (>ERKO) and double knockout (>ERKO/AERKO) mice show marked obesity, 18, 19 whereas ER-A knockout (AERKO) mice are of normal weight. However, >ERKO mice also have elevated 17A-estradiol levels, thus increasing ER-A signaling. 20 When ER-A signaling in >ERKO is removed by ovariectomy, fat-pad weights and adipocyte size decrease, 20 suggesting adipogenic effects of ER-A signaling. Furthermore, in humans, Shin et al 16 reported that participants with more ER-A than ER-> in omental adipose tissue had a greater degree of adiposity.
In vitro, the ER-A agonist DPN had a maximal effect on 11AHSD1 at 1 to 10 nM. Because DPN has its highest specificity for ER-A at these concentrations, 21 these results support our conclusion that activation of ER-A can directly up-regulate 11AHSD1 in adipocytes. These findings are also supported by previous data showing that 17A-estradiol can activate the 11AHSD1 promoter in transfected adipocytes. 22 
CONCLUSIONS
This study implies a link between adipose ER-A signaling and local glucocorticoid metabolism that may promote adipogenesis. This is particularly relevant in the postmenopausal setting, where the beneficial effects of activating ER-> are diminished because of a decrease in circulating 17A-estradiol levels and may contribute to the increase in obesity observed in postmenopausal women.
